Therapeutic Implication of Human Bone Marrow Mesenchymal Stem Cell-Conditioned Medium to Reduce Cystogenic Potential of CD133+ Renal Progenitor Cells of Human Polycystic Kidneys

Authors: Ehsan Ehsani, Sara Hajibabaei, Farid Dadkhah and Reza Moghadasali*

DOI: 10.23880/jes-16000135

Volume 4, Issue 1

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder in which, epithelial cells are somehow dedifferentiated but highly proliferative and form renal cysts. There are also proliferative CD133+ renal progenitor cells in an ADPKD kidney. Among several therapeutic strategies that exist to heal ADPKD, bone marrow mesenchymal stem cells (BMMSC) are of great interest. So, we examined human BM-MSC-condition medium (hBM-MSC-CM) effects on polycystic CD133+ renal progenitor cells. For this purpose, polycystic CD133+ renal progenitor cells were isolated from patients undergoing nephrectomy for kidney transplantation. Differentiation and cystogenic potentials of polycystic CD133+ renal progenitor cells were evaluated using hBM-MSC-CM. Polycystic-lining cells expressed CD133 as a renal progenitor cell marker. These cells were more proliferative and presented a defective epithelial differentiation phenotype compared to normal kidney CD133+ renal progenitor cells. Also, they were not able to express differentiated tubular epithelial cell markers such as E-cadherin and ZO-1. Moreover, polycystic CD133+ renal progenitor cells, in contrast to normal CD133+ renal progenitor cells, formed cysts in a three-dimensional (3D) culture system. hBM-MSC-CM treatment decreased proliferation and cystogenesis, but increased differentiation of polycystic CD133+ renal progenitor cells in vitro. All in all, hBM-MSC-CM could decrease the proliferation and cystogenesis through induction of differentiation in polycystic CD133+ renal progenitor cells.

Keywords: Autosomal Dominant Polycystic Kidney Disease; CD133+ Renal Progenitor Cells; Bone Marrow Mesenchymal Stem Cells; Cystogenesis

View PDF